HONG KONG, Jun 28, 2021 - (ACN Newswire via SEAPRWire.com) - A leading player in China's independent esoteric clinical testing service provider - Kindstar Globalgene Technology, Inc. ("Kindstar Globalgene" or the "Company", together with its subsidiaries, the "Group", stock code: 9960.HK), today announced the proposed listing of its shares on the Main Board of The Stock Exchange of Hong Kong Limited ("Hong Kong Stock Exchange"). Kindstar Globalgene plans to offer 226,405,000 Shares (subject to the Over-allotment Option), of which 203,764,500 Shares will be International Offer Shares (subject to reallocation and the Over-allotment Option), representing 90% of the initial offer shares; the remaining 22,640,500 Shares will be Hong Kong Offer Shares (subject to reallocation), representing 10% of the initial offer shares. Offer Price is between HK$8.60 and HK$9.78 per Share. Kindstar Globalgene will open for Hong Kong Public Offering in Hong Kong at 9 a.m., June 29, 2021 (Tuesday), and close at 12:00 noon, July 7, 2021 (Wednesday). Dealings in shares of Kindstar Globalgene on the Main Board of the Hong Kong Stock Exchange is expected to commence on July 16, 2021 (Friday). The shares wil...